Omaha

Running trials

• Not yet recruiting

  RYZ711 Diagnostic Platform Study

  NCT07862582· Phase 1/2· Source

• Recruiting

  Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

  NCT06726161· Phase 1/2· Source

• Recruiting

  Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

  NCT06590857· Phase 1/2· Source

• Active, not recruiting

  Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

  NCT05595460· Phase 1· Source

• Active, not recruiting

  Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

  NCT05477576· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.